endpoints

Can­cer vac­cine da­ta from #ES­MO26; Trea­sury pro­pos­al could curb Chi­na in­vest­ment; and more

Hello from Madrid, and welcome back to Endpoints Weekly! I’m at #ESMO26 with my colleagues Ayisha Sharma and Reynald ...
endpoints

Swiss biotech Wind­ward Bio files for Nas­daq IPO to fund Chi­na-de­rived as­sets and in-house R&D

Basel-based Windward Bio filed for Nasdaq IPO as $WWB, advancing WIN378 and WIN027 from Kelun-Biotech, Harbour BioMed, and Qyuns for asthma, COPD, and eczema.
endpoints

Q&A: Bris­tol My­ers’ Lynelle Hoch on au­toim­mune CAR-T safe­ty chal­lenges, new pa­tient death

Bristol Myers’ cell therapy chief Lynelle Hoch explains the reagent behind its autoimmune CAR-T pause and a puzzling MS trial ...
endpoints

Roche taps Zymeworks in up to $813M deal for pre­clin­i­cal T cell en­gager

The Swiss pharma is teaming up with Zymeworks, paying $55 million upfront for worldwide rights to a trispecific T cell ...